Healthcare [ 10/13 ] | Biotechnology [ 87/159 ]
NASDAQ | Common Stock
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.
The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 15, 23 | -0.44 Decreased by -1.37 K% | -0.67 Increased by +34.33% |
| Sep 13, 23 | -0.04 Decreased by -33.33% | -0.04 |
| Jul 27, 23 | -0.03 Increased by +25% | -0.04 Increased by +25% |
| Mar 15, 23 | -0.06 Decreased by -100% | -0.04 Decreased by -50% |
| Dec 12, 22 | -0.03 Increased by +25% | -0.04 Increased by +25% |
| Sep 13, 22 | -0.03 Increased by 0% | -0.07 Increased by +57.14% |
| Jul 19, 22 | -0.04 Decreased by -300% | -0.03 Decreased by -33.33% |
| Mar 15, 22 | -0.03 Decreased by -76.47% | -0.02 Decreased by -50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Oct 31, 23 | 0 Decreased by N/A% | -2.91 M Increased by +6.67% | Decreased by N/A% Decreased by N/A% |
| Jul 31, 23 | 0 Decreased by N/A% | -3.53 M Decreased by -16.1% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 23 | 0 Decreased by N/A% | -3.31 M Increased by +14.5% | Decreased by N/A% Decreased by N/A% |
| Jan 31, 23 | 0 Decreased by N/A% | -5.43 M Decreased by -110.96% | Decreased by N/A% Decreased by N/A% |
| Oct 31, 22 | 0 Decreased by N/A% | -3.11 M Increased by +13.51% | Decreased by N/A% Decreased by N/A% |
| Jul 31, 22 | 0 Decreased by N/A% | -3.04 M Decreased by -30.98% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 22 | 0 Decreased by N/A% | -3.87 M Decreased by -207.6% | Decreased by N/A% Decreased by N/A% |
| Jan 31, 22 | 0 Decreased by N/A% | -2.57 M Decreased by -129.95% | Decreased by N/A% Decreased by N/A% |